Key result
Semaglutide lacks reported data on peri-operative cardiovascular outcomes in diabetes in the provided abstract.
Semaglutide's peri-operative cardiovascular impact in diabetes remains unreported; leaves open key questions for surgical risk assessment and dedicated trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Castrillón et al. (2025) studied diabetes. semaglutide was evaluated on peri-operative cardiovascular outcomes. The impact of semaglutide on peri-operative cardiovascular outcomes in diabetes was not reported in the provided abstract text.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: